PT - JOURNAL ARTICLE AU - Jeewandara, Chandima AU - Jayathilaka, Deshni AU - Ranasinghe, Diyanath AU - Hsu, Nienyun Sharon AU - Ariyaratne, Dinuka AU - Jayadas, Tibutius Thanesh AU - Madushanka, Deshan AU - Lindsey, Benjamin B. AU - Gomes, Laksiri AU - Parker, Matthew D. AU - Wijewickrama, Ananda AU - Karunaratne, Malika AU - Ogg, Graham S. AU - de Silva, Thushan I. AU - Malavige, Gathsaurie Neelika TI - Genomic and epidemiological analysis of SARS-CoV-2 viruses in Sri Lanka AID - 10.1101/2021.05.05.21256384 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.05.21256384 4099 - http://medrxiv.org/content/early/2021/06/02/2021.05.05.21256384.short 4100 - http://medrxiv.org/content/early/2021/06/02/2021.05.05.21256384.full AB - Background In order to understand the molecular epidemiology of SARS-CoV-2 in Sri Lanka, since March 2020, we carried out genomic sequencing overlaid on available epidemiological data until April 2021.Methods Whole genome sequencing was carried out on diagnostic sputum or nasopharyngeal swabs from 373 patients with COVID-19. Molecular clock phylogenetic analysis was undertaken to further explore dominant lineages.Results The B.1.411 lineage was most prevalent, which was established in Sri Lanka and caused outbreaks throughout the country until March 2021. The estimated time of the most recent common ancestor of this lineage was 29th June 2020 (95% lower and upper bounds 23rd May to 30th July), suggesting cryptic transmission may have occurred, prior to a large epidemic starting in October 2020. Returning travellers were identified with infections caused by lineage B.1.258, as well as the more transmissible B.1.1.7 lineage, which has replaced B.1.411 to fuel the ongoing large outbreak in the country.Conclusions The large outbreak that started in early October, is due to spread of a single virus lineage, B.1.411 until the end of March 2021, when B.1.1.7 emerged and became the dominant lineage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office for support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was obtained by the Ethics Review Committee of the University of Sri Jayewardenepura.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available within the manuscript and the supporting information files.